Dezecapavir vs VH4004280 (VH-280)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV capsid · full HIV pipeline
Dezecapavir
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This Phase 2 trial was randomized, double-blind (participant and investigator), and placebo-controlled, with 44 participants allocated across multiple dose groups of VH4004280 and VH4011499. The primary endpoint was the maximum change in plasma HIV-1 RNA during 10-day monotherapy; posted results for VH4011499 show mean declines of about -1.8 to -2.2 log10 in active arms versus -0.18 log10 in placebo, but no p-values or confidence intervals are reported. Because the groups are very small (6-7 active vs 3 placebo) and the statistical significance of the primary comparison is not documented, this constitutes real but limited evidence.
Next expected readout: February 2027 · NCT07934719 (registry estimate)
Reported efficacy
Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) (unclear)
Result source: NCT06039579
VH4004280 (VH-280)
Developed by ViiV Healthcare
NCT06039579 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled parallel-group trial, but the primary endpoint is a surrogate biomarker (plasma HIV-1 RNA) rather than a hard clinical/endoscopic outcome, and the sample size is small (only 3-7 participants per arm), which limits precision and power. Although the posted results show large antiviral effects in the active arms relative to placebo, no statistical significance testing or confidence intervals are provided, so the primary comparison cannot be confirmed as met.
Reported efficacy
Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11); Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) (unclear)
Result source: NCT06039579
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dezecapavir | VH4004280 (VH-280) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Dezecapavir
- —Not reported
- VH4004280 (VH-280)
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Dezecapavir
- —Not reported
- VH4004280 (VH-280)
- —Not reported
CD4 count, change (week 48)
- Dezecapavir
- —Not reported
- VH4004280 (VH-280)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Dezecapavir: 5 of 6 rows · VH4004280 (VH-280): 5 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dezecapavir | VH4004280 (VH-280) |
|---|---|---|
| HIV-1 RNA absolute change · log Maximum change compared to Baseline (Day 1) | -1.834 vs -0.176 placebo logDose Level 1a,b NCT06039579 · Phase 2 · combination · HIV · phase 2 show 2 more doses-1.797 vs -0.176 placebo logDose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 -2.165 vs -0.176 placebo logPre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 | -1.056 vs -0.07 placebo logDose Level 1a,b NCT06039579 · Phase 2 · combination · HIV · phase 2 show 2 more doses-1.391 vs -0.07 placebo logDose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 -1.983 vs -0.07 placebo logPre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -1.801 log @ 1.57wkDose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 2 more doses-1.75 log @ 1.57wkDose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 -2.165 log @ 1.57wkPre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 | -0.941 log @ 1.57wkDose Level 1a NCT06039579 · Phase 2 · combination · HIV · phase 2 show 2 more doses-1.322 log @ 1.57wkDose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 -1.939 log @ 1.57wkPre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 |
| Dropout rate | 0%Dose Level 1c NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%1875 mg PiB NCT05393271 · Phase 1 · monotherapy 0%625 mg PiB NCT05393271 · Phase 1 · monotherapy 0%400 mg PiB NCT05393271 · Phase 1 · monotherapy 0%300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg Tablet NCT05393271 · Phase 1 · monotherapy 0%125 mg PiB NCT05393271 · Phase 1 · monotherapy 0%25 mg PiB NCT05393271 · Phase 1 · monotherapy | 0%Dose Level 1c NCT06039579 · Phase 2 · combination · HIV · phase 2 show 16 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%900 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%350 mg NCT05163522 · Phase 1 · monotherapy 0%250 mg + Midazolam NCT05163522 · Phase 1 · combination 0%150 mg NCT05163522 · Phase 1 · monotherapy 0%100 mg NCT05163522 · Phase 1 · monotherapy 14.3%50 mg NCT05163522 · Phase 1 · monotherapy 0%10 mg NCT05163522 · Phase 1 · monotherapy |
| Discontinued due to AEs | —Dose Level 1c NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —1875 mg PiB NCT05393271 · Phase 1 · monotherapy —625 mg PiB NCT05393271 · Phase 1 · monotherapy —400 mg PiB NCT05393271 · Phase 1 · monotherapy —300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination —200 mg PiB NCT05393271 · Phase 1 · monotherapy —200 mg PiB NCT05393271 · Phase 1 · monotherapy —200 mg Tablet NCT05393271 · Phase 1 · monotherapy —125 mg PiB NCT05393271 · Phase 1 · monotherapy —25 mg PiB NCT05393271 · Phase 1 · monotherapy | —Dose Level 1c NCT06039579 · Phase 2 · combination · HIV · phase 2 show 16 more results—Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —900 mg NCT05163522 · Phase 1 · monotherapy —450 mg NCT05163522 · Phase 1 · monotherapy —450 mg NCT05163522 · Phase 1 · monotherapy —350 mg NCT05163522 · Phase 1 · monotherapy —250 mg + Midazolam NCT05163522 · Phase 1 · combination —150 mg NCT05163522 · Phase 1 · monotherapy —100 mg NCT05163522 · Phase 1 · monotherapy —50 mg NCT05163522 · Phase 1 · monotherapy —10 mg NCT05163522 · Phase 1 · monotherapy |
| Serious AEs | —Dose Level 1c NCT06039579 · Phase 2 · combination · HIV · phase 2 show 17 more results0%Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%1875 mg PiB NCT05393271 · Phase 1 · monotherapy 0%625 mg PiB NCT05393271 · Phase 1 · monotherapy 0%400 mg PiB NCT05393271 · Phase 1 · monotherapy 0%300 mg + Midazolam (MDZ) PiB NCT05393271 · Phase 1 · combination 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg PiB NCT05393271 · Phase 1 · monotherapy 0%200 mg Tablet NCT05393271 · Phase 1 · monotherapy 0%125 mg PiB NCT05393271 · Phase 1 · monotherapy 0%25 mg PiB NCT05393271 · Phase 1 · monotherapy | —Dose Level 1c NCT06039579 · Phase 2 · combination · HIV · phase 2 show 16 more results0%Dose Level 1 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 1 NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Dose Level 2 NCT06039579 · Phase 2 · combination · HIV · phase 2 —Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · combination · HIV · phase 2 0%Pre-specified Dose NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 0%900 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%450 mg NCT05163522 · Phase 1 · monotherapy 0%350 mg NCT05163522 · Phase 1 · monotherapy 0%250 mg + Midazolam NCT05163522 · Phase 1 · combination 0%150 mg NCT05163522 · Phase 1 · monotherapy 0%100 mg NCT05163522 · Phase 1 · monotherapy 0%50 mg NCT05163522 · Phase 1 · monotherapy 0%10 mg NCT05163522 · Phase 1 · monotherapy |
| Most frequent reported AEs | Dose Level 1c influenza 14.3% (placebo 33.3%) proteinuria 14.3% (placebo 0%) rash 14.3% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 show 14 more resultsDose Level 1 headache 14.3% (placebo 0%) upper respiratory tract infection 14.3% (placebo 0%) alanine aminotransferase increased 0% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Dose Level 2 arthralgia 16.7% (placebo 0%) dermatophytosis 16.7% (placebo 0%) ear pain 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Dose Level 2 asthenia 16.7% (placebo 0%) dermatitis acneiform 16.7% (placebo 0%) diarrhoea 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Pre-specified Dose nausea 28.6% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) aspartate aminotransferase increased 14.3% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose vessel puncture site haematoma 28.6% (placebo 0%) headache 14.3% (placebo 0%) hypokalaemia 14.3% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 1875 mg PiB total bile acids increased 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 625 mg PiB gastroenteritis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 400 mg PiB dry skin 16.7% (placebo 0%) skin abrasion 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 300 mg + Midazolam (MDZ) PiB somnolence 25% (placebo 0%) dizziness 12.5% (placebo 0%) feeling abnormal 12.5% (placebo 0%) NCT05393271 · Phase 1 · combination 200 mg PiB activated partial thromboplastin time prolonged 33.3% (placebo 0%) blood triglycerides increased 16.7% (placebo 0%) lipase increased 16.7% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 200 mg PiB diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 0%) nausea 33.3% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 200 mg Tablet medical device site dermatitis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 125 mg PiB medical device site dermatitis 16.7% (placebo 0%) abdominal pain 0% (placebo 0%) activated partial thromboplastin time prolonged 0% (placebo 0%) NCT05393271 · Phase 1 · monotherapy 25 mg PiB blood creatine phosphokinase increased 16.7% (placebo 20%) haematocrit decreased 16.7% (placebo 0%) haemoglobin decreased 16.7% (placebo 0%) NCT05393271 · Phase 1 · monotherapy | Dose Level 1c transaminases increased 16.7% (placebo 0%) alanine aminotransferase increased 0% (placebo 0%) arthralgia 0% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 show 14 more resultsDose Level 1 headache 16.7% (placebo 0%) periodontitis 16.7% (placebo 0%) rhinitis allergic 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 Dose Level 2 blood creatinine increased 33.3% (placebo 0%) pyrexia 16.7% (placebo 0%) thrombocytopenia 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Dose Level 2 blood creatinine increased 33.3% (placebo 0%) hypertriglyceridaemia 33.3% (placebo 0%) cough 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose cough 16.7% (placebo 0%) pharyngitis 16.7% (placebo 0%) rhinitis 16.7% (placebo 0%) NCT06039579 · Phase 2 · combination · HIV · phase 2 Pre-specified Dose alanine aminotransferase increased 16.7% (placebo 0%) dengue fever 16.7% (placebo 0%) urticaria 16.7% (placebo 0%) NCT06039579 · Phase 2 · monotherapy · HIV · phase 2 900 mg headache 16.7% (placebo 0%) abdominal discomfort 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 10%) NCT05163522 · Phase 1 · monotherapy 450 mg abdominal discomfort 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 10%) amylase increased 0% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 450 mg alanine aminotransferase increased 16.7% (placebo 10%) amylase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 10%) NCT05163522 · Phase 1 · monotherapy 350 mg alanine aminotransferase increased 16.7% (placebo 10%) aspartate aminotransferase increased 16.7% (placebo 10%) bile acids increased 16.7% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 250 mg + Midazolam fatigue 62.5% (placebo 0%) blood creatine phosphokinase increased 25% (placebo 0%) low density lipoprotein increased 25% (placebo 0%) NCT05163522 · Phase 1 · combination 150 mg abdominal discomfort 0% (placebo 0%) alanine aminotransferase increased 0% (placebo 10%) amylase increased 0% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 100 mg dyslipidaemia 33.3% (placebo 0%) bile acids increased 16.7% (placebo 0%) blood bilirubin increased 16.7% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 50 mg abdominal discomfort 28.6% (placebo 0%) diarrhoea 28.6% (placebo 0%) body temperature increased 14.3% (placebo 0%) NCT05163522 · Phase 1 · monotherapy 10 mg chapped lips 16.7% (placebo 0%) dermatitis contact 16.7% (placebo 10%) dry mouth 16.7% (placebo 0%) NCT05163522 · Phase 1 · monotherapy |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bThe assessment timepoint is not available for both results.
- cPopulation comparability has not been reviewed for 9 of these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dezecapavir's landscape · VH4004280 (VH-280)'s landscape